Cited by 393Adrenal and Paraganglionic TumorsNeuroendocrine Tumor Research AdvancesRenal cell carcinoma treatment

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma

Open access

Kimura, Noriko, Takayanagi, Ryoichi, Takizawa, Nae, Itagaki, Eiji, Katabami, Takayuki, Kakoi, Narihiko, Rakugi, Hiromi, Ikeda, Yukihiro, Tanabe, Akiyo, Nigawara, Takeshi, Ito, Sadayoshi, Kimura, Itaru, Naruse, Mitsuhide, _, _·2014·Endocrine Related Cancer

DOI 10.1530/erc-13-0494

Open this paper in CoChat — free account Open PDF

Abstract

Phaeochromocytomas (PHEO) and paragangliomas are rare catecholamine-producing tumours. Although 10-30% of these tumours metastasise, histopathological criteria to discriminate malignant from benign tumours have not been established; therefore, reliable histopathological markers predicting metastasis are urgently required. A total of 163 tumours, including 40 metastatic tumours, collected by the Phaeochromocytoma Study Group in Japan (PHEO-J) were analysed using a system called grading system for adrenal phaeochromocytoma and paraganglioma (GAPP). The tumours were scored based on GAPP criteria as follows: histological pattern, cellularity, comedo-type necrosis, capsular/vascular invasion, Ki67 labelling index and catecholamine type. All tumours were scored from 0 to 10 points and were graded as one of the three types: well-differentiated (WD, 0-2 points), moderately differentiated (MD, 3-6 points) and poorly differentiated (PD, 7-10 points). GAPP scores of the non-metastatic and metastatic groups were 2.08±0.17 and 5.33±0.43 (mean±s.e.m., P<0.001) respectively. There was a significant negative correlation between the GAPP score and the interval until metastasis (r=-0.438, P<0.01). The mean number of years until metastasis after the initial operation was 5.5±2.6 years. The study included 111 WD, 35 MD and 17 PD types. The five-year survival of these groups was 100, 66.8 and 22.4% respectively. In addition, negative immunoreactivity for succinate dehydrogenase gene subunit B (SDHB) was observed in 13 (8%) MD or PD tumours and ten of the 13 (77%) had metastases. Our data indicate that a combination of GAPP classification and SDHB immunohistochemistry might be useful for the prediction of metastasis in these tumours.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1530/erc-13-0494

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Distinct Clinical Features of Paraganglioma Syndromes Associated With <EMPH TYPE="ITAL">SDHB</EMPH> and <EMPH TYPE="ITAL">SDHD</EMPH> Gene Mutations
Neumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893
Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases
Thompson, L. D. R. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200205000-00002 · Cited by 715
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis
van Nederveen, F. H., Gaal, J., Favier, J., Korpershoek, E., Oldenburg, R. A., de Bruyn, E. M., Sleddens, H. F. B. M., Derkx, P., Rivière, J., Dannenberg, H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70164-0 · Cited by 554
Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.
Gimenez‐Roqueplo, A., Favier, J., Rustin, P., Rieubland, C., Crespin, M., Nau, V., Kien, P. K. V., Corvol, P. L., Plouin, P., & Jeunemaı̂tre, X. (2003) · PubMed · Cited by 542
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas
Castro‐Vega, L. J., Buffet, A., de Cubas, A. A., Cascón, A., Menara, M., Khalifa, E., Amar, L., Azriel, S., Bourdeau, I., Chabre, O., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt639 · Cited by 412
Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status
Eisenhofer, G., Lenders, J. W. M., Siegert, G., Bornstein, S. R., Friberg, P., Milosevic, D., Mannelli, M., Linehan, W. M., Adams, K. T., Timmers, H. J. L. M., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.07.016 · Cited by 375
The Succinate Dehydrogenase Genetic Testing in a Large Prospective Series of Patients with Paragangliomas
Burnichon, N., Rohmer, V., Amar, L., Herman, P., Leboulleux, S., Darrouzet, V., Niccoli, P., Gaillard, D. A., Chabrier, G., Chabolle, F., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2504 · Cited by 374
Histopathology of benign versus malignant sympathoadrenal paragangliomas: Clinicopathologic study of 120 cases including unusual histologic features
Linnoila, R. I., Keiser, H. R., Steinberg, S. M., & Lack, E. E. (1990) · Human Pathology · doi:10.1016/0046-8177(90)90155-x · Cited by 373
The diagnosis and management of malignant phaeochromocytoma and paraganglioma
Chrisoulidou, A., Kaltsas, G., Ilias, Ι., & Grossman, A. B. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0074 · Cited by 310
AFIP Atlas of Tumor Pathology
Start, R. D. (2000) · Histopathology · doi:10.1046/j.1365-2559.2000.01097.x · Cited by 304

Flagged first, then by citations

Show all 25 references

Research works printed but not linked: 5

Gimenez-Roqueplo, 2003, Cancer Research, 63, 5615
2013, Molecular and cellular endocrinology, 386, 92
Nagura, 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 12, 1107
2011, Endocrine Reviews, 32
1991, ARCHIVES OF PATHOLOGY LABORATORY MEDICINE, 115, 484

Sorted by citations

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal
Rindi, G., Klimstra, D. S., Abedi‐Ardekani, B., Asa, S. L., Bosman, F. T., Brambilla, E. M., BUSAM, K. J., de Krijger, R. R., Dietel, M., El‐Naggar, A. K., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0110-y · Cited by 1,164
Pheochromocytoma and Paraganglioma
Neumann, H. P. H., Young, W. F., & Eng, C. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1806651 · Cited by 736
European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma
Plouin, P., Amar, L., Dekkers, O. M., Faßnacht, M., Gimenez‐Roqueplo, A., Lenders, J. W. M., Lussey‐Lepoutre, C., Steichen, O., & _, _. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0033 · Cited by 475
Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours
Lam, A. K.-Y. (2017) · Endocrine Pathology · doi:10.1007/s12022-017-9484-5 · Cited by 463
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Faßnacht, M., Assié, G., Baudin, É., Eisenhofer, G., de la Fouchardière, C., Haak, H. R., de Krijger, R. R., Porpiglia, F., Terzolo, M., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2099 · Cited by 446
Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas
Mete, Ö., Asa, S. L., Gill, A. J., Kimura, N., de Krijger, R. R., & Tischler, A. S. (2022) · Endocrine Pathology · doi:10.1007/s12022-022-09704-6 · Cited by 432
Self-citation
Personalized Management of Pheochromocytoma and Paraganglioma
Nölting, S., Bechmann, N., Taïeb, D., Beuschlein, F., Faßnacht, M., Kroiß, M., Eisenhofer, G., Grossman, A. B., & Pacák, K. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab019 · Cited by 441
Adrenal incidentaloma
Sherlock, M., Scarsbrook, A., Abbas, A., Fraser, S., Limumpornpetch, P., Dineen, R., & Stewart, P. M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa008 · Cited by 347
“(121) developed a less involved scoring system for prediction of metastases, Grading of Adrenal Pheochromocytoma and Paraganglioma (GAPP) consisting of a smaller number of pathological parameters with weighted scoring (1 or 2 points) including histological pattern; cellularity; comedo necrosis; capsular/vascular invas…”
Background
New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification
Crona, J., Taïeb, D., & Pacák, K. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00062 · Cited by 330
SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T)
Papathomas, T. G., Oudijk, L., Persu, A., Gill, A. J., van Nederveen, F. H., Tischler, A. S., Tissier, F., Volante, M., Matías‐Guiu, X., Smid, M., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.41 · Cited by 228
Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms
Mete, Ö., & Wenig, B. M. (2022) · Head and Neck Pathology · doi:10.1007/s12105-022-01435-8 · Cited by 177
Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine
Nölting, S., Ullrich, M., Pietzsch, J., Ziegler, C. G., Eisenhofer, G., Grossman, A. B., & Pacák, K. (2019) · Cancers · doi:10.3390/cancers11101505 · Cited by 173
The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations
Asa, S. L., Ezzat, S., & Mete, Ö. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7090280 · Cited by 167
Pheochromocytoma and Paraganglioma
Fishbein, L. M. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.09.006 · Cited by 161
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma
Fishbein, L. M., Rivero, J. D., Else, T., Howe, J. R., Asa, S. L., Cohen, D. L., Dahia, P. L. M., Fraker, D. L., Goodman, K. A., Hope, T. A., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001792 · Cited by 161
Pathology and genetics of phaeochromocytoma and paraganglioma
Turchini, J., Cheung, V. K.-Y., Tischler, A. S., de Krijger, R. R., & Gill, A. J. (2017) · Histopathology · doi:10.1111/his.13402 · Cited by 148
Genotype–phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis
Crona, J., Lamarca, Á., Ghosal, S., Welin, S., Skogseid, B. M., & Pacák, K. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0024 · Cited by 140
Review of Pediatric Pheochromocytoma and Paraganglioma
Bholah, R., & Bunchman, T. E. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00155 · Cited by 137
Pheochromocytoma
Farrugia, F., & Charalampopoulos, A. A. (2019) · Endocrine Regulations · doi:10.2478/enr-2019-0020 · Cited by 123
Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma
Koh, J.-M., Ahn, S. H., Kim, H., Kim, B.-J., Sung, T.-Y., Kim, Y. H., Hong, S. J., Song, D. E., & Lee, S. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187398 · Cited by 114
Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era
Pillai, S., Gopalan, V., Smith, R. A., & Lam, A. K.-Y. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.022 · Cited by 113
Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future
Rosa, S. L. (2023) · Endocrine Pathology · doi:10.1007/s12022-023-09755-3 · Cited by 102
Fluorescence/Colorimetry/Smartphone Triple-Mode Sensing of Dopamine by a COF-Based Peroxidase-Mimic Platform
Yue, J., Song, L.-P., Wang, Y.-T., Yang, P., Ma, Y., & Tang, B. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03179 · Cited by 101
The new 4th edition World Health Organization classification for thyroid tumors, Asian perspectives
Kakudo, K., Bychkov, A., Bai, Y., Li, Y., Liu, Z., & Jung, C. K. (2018) · Pathology International · doi:10.1111/pin.12737 · Cited by 98
Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma
Calsina, B., Piñeiro-Yáñez, E., Martínez‐Montes, Á. M., Caleiras, E. J., Fernández-Sanromán, Á., Monteagudo, M., Torres‐Pérez, R., Torre, C. F., Pulgarín-Alfaro, M., Gil, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36769-6 · Cited by 103
Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems
Wachtel, H., Hutchens, T., Baraban, E. G., Schwartz, L. E., Montone, K. T., Baloch, Z. W., LiVolsi, V. A., Krumeich, L. N., Fraker, D. L., Nathanson, K. L., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa608 · Cited by 106
Metastatic Pheochromocytomas and Abdominal Paragangliomas
Granberg, D. O., Juhlin, C. C., & Falhammar, H. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa982 · Cited by 96
Risk Stratification on Pheochromocytoma and Paraganglioma from Laboratory and Clinical Medicine
Kimura, N., Takekoshi, K., & Naruse, M. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7090242 · Cited by 95
Self-citation
The Value of Histological Algorithms to Predict the Malignancy Potential of Pheochromocytomas and Abdominal Paragangliomas—A Meta-Analysis and Systematic Review of the Literature
Stenman, A., Zedenius, J., & Juhlin, C. C. (2019) · Cancers · doi:10.3390/cancers11020225 · Cited by 94
Paraganglioma of the Head and Neck: A Review
Sandow, L., Thawani, R., Kim, M. S., & Heinrich, M. C. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.10.002 · Cited by 88
Clinicopathological characteristics of pheochromocytoma/paraganglioma and screening of prognostic markers
Lei, J., Qu, T., Cha, L., Tian, L., Qiu, F., Guo, W., Cao, J., Sun, C., & Zhou, B. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27358 · Cited by 89
COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas
Pierre, C., Agopiantz, M., Brunaud, L., Battaglia-Hsu, S.-F., Max, A., Pouget, C., Nominé-Criqui, C., Lomazzi, S., Vignaud, J.-M., Weryha, G., et al. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02553-5 · Cited by 83
SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma
Assadipour, Y., Sadowski, S. M., Alimchandani, M., Quezado, M., Steinberg, S. M., Nilubol, N., Patel, D., Prodanov, T., Pacák, K., & Kebebew, E. (2016) · Surgery · doi:10.1016/j.surg.2016.05.050 · Cited by 79
Clinical implications of the oncometabolite succinate in SDHx ‐mutation carriers
Eijkelenkamp, K., Osinga, T. E., Links, T. P., & van der Horst‐Schrivers, A. N. A. (2019) · Clinical Genetics · doi:10.1111/cge.13553 · Cited by 78
65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma
Neumann, H. P. H., Young, W. F., Krauß, T., Bayley, J., Schiavi, F., Opocher, G., Boedeker, C. C., Tirosh, A., Castinetti, F., Ruf, J., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0085 · Cited by 73
Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort
Pamporaki, C., Berends, A. M. A., Filippatos, A., Prodanov, T., Meuter, L., Prejbisz, A., Beuschlein, F., Faßnacht, M., Timmers, H. J. L. M., Nölting, S., et al. (2023) · The Lancet Digital Health · doi:10.1016/s2589-7500(23)00094-8 · Cited by 70
15 YEARS OF PARAGANGLIOMA: Pathology of pheochromocytoma and paraganglioma
Tischler, A. S., & de Krijger, R. R. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0261 · Cited by 66
Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry
Juhlin, C. C. (2021) · Endocrine Pathology · doi:10.1007/s12022-021-09675-0 · Cited by 69
Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment
Zethoven, M., Martelotto, L. G., Pattison, A., Bowen, B., Balachander, S., Flynn, A., Rossello, F. J., Hogg, A., Miller, J. A., Fryšák, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34011-3 · Cited by 67
Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma
Berends, A. M. A., Eisenhofer, G., Fishbein, L. M., van der Horst‐Schrivers, A. N. A., Kema, I. P., Links, T. P., Lenders, J. W. M., & Kerstens, M. N. (2019) · Cancers · doi:10.3390/cancers11081121 · Cited by 68
What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics
Juhlin, C. C., Bertherat, J. Y., Giordano, T. J., Hammer, G. D., Sasano, H., & Mete, Ö. (2021) · Endocrine Pathology · doi:10.1007/s12022-021-09667-0 · Cited by 63
Pheochromocytomas and Abdominal Paragangliomas: A Practical Guidance
Calissendorff, J., Juhlin, C. C., Bancos, I., & Falhammar, H. (2022) · Cancers · doi:10.3390/cancers14040917 · Cited by 61
A clinical prediction model to estimate the metastatic potential of pheochromocytoma/paraganglioma: ASES score
Cho, Y. Y., Kwak, M. K., Lee, S., Ahn, S. H., Kim, H., Suh, S., Kim, B., Song, K., Kim, J. H., Kim, J. H., et al. (2018) · Surgery · doi:10.1016/j.surg.2018.05.001 · Cited by 61
A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: Beyond phaeochromocytoma and paraganglioma
MacFarlane, J., Seong, K. C., Bisambar, C., Madhu, B., Allinson, K. S. J., Marker, A. J., Warren, A. Y., Park, S., Giger, O., Challis, B., et al. (2020) · Clinical Endocrinology · doi:10.1111/cen.14289 · Cited by 64
Genetic bases of pheochromocytoma and paraganglioma
Cascón, A., Calsina, B., Monteagudo, M., Mellid, S., Díaz‐Talavera, A., Currás-Freixes, M., & Robledo, M. (2022) · Journal of Molecular Endocrinology · doi:10.1530/jme-22-0167 · Cited by 65
Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas
Kim, K. Y., Kim, J. H., Hong, A. R., Seong, M., Lee, K. E., Kim, S., Kim, S. W., Shin, C. S., & Kim, S. Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168413 · Cited by 52
Pheochromocytomas and Paragangliomas: New Developments with Regard to Classification, Genetics, and Cell of Origin
Koopman, K., Gaal, J., & de Krijger, R. R. (2019) · Cancers · doi:10.3390/cancers11081070 · Cited by 55
Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: Results from a multicenter observational registry
Yoshinaga, K., Oriuchi, N., Wakabayashi, H., Tomiyama, Y., Jinguji, M., Higuchi, T., Kayano, D., Fukuoka, M., Inaki, A., Toratani, A., et al. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej14-0211 · Cited by 48
Diagnosis and Management of Pheochromocytomas and Paragangliomas: A Guide for the Clinician
Sharma, S., & Fishbein, L. M. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.07.027 · Cited by 47
Clinical evaluation and treatment of phaeochromocytoma
Davison, A. S., Jones, D. M., Ruthven, S., Helliwell, T. R., & Shore, S. (2017) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563217739931 · Cited by 46
Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting
Thompson, L. D. �., Gill, A. J., Asa, S. L., Clifton-Bligh, R. J., de Krijger, R. R., Kimura, N., Komminoth, P., Lack, E. E., Lenders, J. W. M., Lloyd, R. V., et al. (2020) · Human Pathology · doi:10.1016/j.humpath.2020.04.012 · Cited by 46
Self-citation
Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy
Parasiliti‐Caprino, M., Lucatello, B. G., Lopez, C., Burrello, J., Maletta, F., Mistrangelo, M., Migliore, E., Tassone, F., Grotta, A. L., Pia, A. R., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0339-y · Cited by 45
Clinicopathological study of SDHB mutation-related pheochromocytoma and sympathetic paraganglioma
Kimura, N., Takekoshi, K., Horii, A., Morimoto, R., Imai, T., Oki, Y., Saito, T., Midorikawa, S., Arao, T., Sugisawa, C., et al. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0530 · Cited by 45
Self-citation
Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience
Choi, Y. M., Sung, T., Kim, W. G., Lee, J. J., Ryu, J., Kim, T. Y., Kim, W. B., Hong, S. J., Song, D. E., & Shong, Y. K. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.24063 · Cited by 43
A Guide to Pheochromocytomas and Paragangliomas
Guilmette, J. M., & Sadow, P. M. (2019) · Surgical pathology clinics · doi:10.1016/j.path.2019.08.009 · Cited by 44
What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?
Papathomas, T. G., Suurd, D. P. D., Pacák, K., Tischler, A. S., Vriens, M. R., Lam, A. K.-Y., & de Krijger, R. R. (2021) · Endocrine Pathology · doi:10.1007/s12022-020-09658-7 · Cited by 40
Old, New, and Emerging Immunohistochemical Markers in Pheochromocytoma and Paraganglioma
Cheung, V. K.-Y., Gill, A. J., & Chou, A. S. Y. (2018) · Endocrine Pathology · doi:10.1007/s12022-018-9534-7 · Cited by 40
Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan
Naruse, M., Satoh, F., Tanabe, A., Okamoto, T., Ichihara, A., Tsuiki, M., Katabami, T., Nomura, M., Tanaka, T., Matsuda, T., et al. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej17-0276 · Cited by 38
Self-citation
Recent advances in the management of pheochromocytoma and paraganglioma
Tanabe, A., & Naruse, M. (2020) · Hypertension Research · doi:10.1038/s41440-020-0531-0 · Cited by 37
Self-citation
Dopamine-Secreting Pheochromocytoma and Paraganglioma
Miyamoto, S., Yoshida, Y., Ozeki, Y., Okamoto, M., Gotoh, K., Masaki, T., Nishida, H., Shibuya, T., Shin, T., Daa, T., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab163 · Cited by 37
Self-citation
Malignant pheochromocytoma and paraganglioma: management options
Corssmit, E. P. M., Snel, M., & Kapiteijn, E. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000589 · Cited by 36
Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma
Dhir, M., Li, W., Hogg, M. E., Bartlett, D. L., Carty, S. E., McCoy, K. L., Challinor, S. M., & Yip, L. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-6074-1 · Cited by 35
Prognostic Utility of the Ki-67 Labeling Index in Follicular Thyroid Tumors: a 20-Year Experience from a Tertiary Thyroid Center
Hellgren, L. S., Stenman, A., Paulsson, J. O., Höög, A., Larsson, C., Zedenius, J., & Juhlin, C. C. (2022) · Endocrine Pathology · doi:10.1007/s12022-022-09714-4 · Cited by 34
Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles
Flynn, A., Pattison, A., Balachander, S., Boehm, E., Bowen, B., Dwight, T., Rossello, F. J., Hofmann, O., Martelotto, L. G., Zethoven, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57595-y · Cited by 37
Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior
Stenman, A., Svahn, F., Hojjat‐Farsangi, M., Zedenius, J., Söderkvist, P., Gimm, O., Larsson, C., & Juhlin, C. C. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001190 · Cited by 33
Paragangliomas of the Head and Neck: A Review of the Latest Diagnostic and Treatment Methods
Palade, D. O., Hainăroșie, R., Zamfir‐Chiru‐Anton, A., Vrînceanu, D., Perțea, M., Tuşaliu, M., Mocanu, F., & Voiosu, C. (2024) · Medicina · doi:10.3390/medicina60060914 · Cited by 32
The systems of metastatic potential prediction in pheochromocytoma and paraganglioma.
Wang, Y., Li, M., Deng, H., Pang, Y., Liu, L., & Guan, X. (2020) · PubMed Central · Cited by 32
Urinary Bladder Paragangliomas
Giubellino, A., Lara‐Otero, K., Martucci, V. L., Huynh, T., Agarwal, P. K., Pacák, K., & Merino, M. J. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000534 · Cited by 31
Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs)
Khatami, F., Amoli, M. M., & Tavangar, S. M. (2018) · Endocrine Regulations · doi:10.2478/enr-2018-0006 · Cited by 31
Pheochromocytomas Most Commonly Present As Adrenal Incidentalomas: A Large Tertiary Center Experience
Aggarwal, S., Prete, A., Chortis, V., Asia, M. F., Sutcliffe, R. P., Arlt, W., Ronchi, C. L., Karavitaki, N., Ayuk, J., & Elhassan, Y. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad401 · Cited by 30
Closing the GAPP on predicting metastases
Eisenhofer, G., & Tischler, A. S. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.41 · Cited by 30
Surgery for advanced adrenal malignant disease: recommendations based on European Society of Endocrine Surgeons consensus meeting
Mihai, R., Crea, C. D., Guérin, C., Torresan, F., Ağcaoğlu, O., Simescu, R., & Walz, M. K. (2024) · British journal of surgery · doi:10.1093/bjs/znad266 · Cited by 30
Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms
Stenman, A., Zedenius, J., & Juhlin, C. C. (2018) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-018-1679-9 · Cited by 28
Histopathological Analysis of Tumor Microenvironment and Angiogenesis in Pheochromocytoma
Gao, X., Yamazaki, Y., Pecori, A., Tezuka, Y., Ono, Y., Omata, K., Morimoto, R., Nakamura, Y., Satoh, F., & Sasano, H. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.587779 · Cited by 28
Perioperative hemodynamic instability in pheochromocytoma and sympathetic paraganglioma patients
Kim, J. H., Lee, H., Kim, S., Yoon, S. B., Kong, S. H., Yu, H. W., Chai, Y. J., Choi, J. Y., Lee, K. E., Lee, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97964-3 · Cited by 27
Top 10 Histological Mimics of Neuroendocrine Carcinoma You Should Not Miss in the Head and Neck
Juhlin, C. C., & Bal, M. M. (2023) · Head and Neck Pathology · doi:10.1007/s12105-022-01521-x · Cited by 26
Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients
Yamazaki, Y., Gao, X., Pecori, A., Nakamura, Y., Tezuka, Y., Omata, K., Ono, Y., Morimoto, R., Satoh, F., & Sasano, H. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.587769 · Cited by 30
Pheochromocytoma
Liu, Z., Ma, J., Jiménez, C., & Zhang, M. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001768 · Cited by 28
Immunohistochemical Expression of Choline Acetyltransferase and Catecholamine-Synthesizing Enzymes in Head-and-Neck and Thoracoabdominal Paragangliomas and Pheochromocytomas
Kimura, N., Shiga, K., Kaneko, K., Oki, Y., Sugisawa, C., Saito, J., Tawara, S., Akahori, H., Sogabe, S., Yamashita, T., et al. (2021) · Endocrine Pathology · doi:10.1007/s12022-021-09694-x · Cited by 26
Self-citation
Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options
Eid, M., Foukal, J., Sochorová, D., Tuček, Š., Starý, K., Kala, Z., Mayer, J., Němeček, R., Trna, J., & Kunovský, L. (2023) · Cancer Medicine · doi:10.1002/cam4.6010 · Cited by 26
Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force
Ku, E. J., Kim, K. J., Kim, J. H., Kim, M. K., Ahn, C. H., Lee, K. A., Lee, S. H., Lee, Y., Park, K. H., Choi, Y. M., et al. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.908 · Cited by 25
Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas
Evenepoel, L., van Nederveen, F. H., Oudijk, L., Papathomas, T. G., Restuccia, D. F., Belt, E. J. T., de Herder, W. W., Feelders, R. A., Franssen, G. J. H., Hamoir, M., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01314 · Cited by 24
Max Schottelius: Pioneer in Pheochromocytoma
Bausch, B., Tischler, A. S., Schmid, K. W., Leijon, H., Eng, C., & Neumann, H. P. H. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00208 · Cited by 24
Composite Pheochromocytoma/Paraganglioma-Ganglioneuroma: A Clinicopathologic Study of Eight Cases with Analysis of Succinate Dehydrogenase
Gupta, S., Zhang, J., & Erickson, L. A. (2017) · Endocrine Pathology · doi:10.1007/s12022-017-9494-3 · Cited by 24
Approach to the Patient With Metastatic Pheochromocytoma and Paraganglioma
Alkaissi, H. R., Taïeb, D., Lin, F. I., Rivero, J. D., Wang, K., Clifton-Bligh, R. J., & Pacák, K. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf259 · Cited by 24
The clinical utility of circulating neuroendocrine gene transcript analysis in well-differentiated paragangliomas and pheochromocytomas
Pęczkowska, M., Ćwikła, J. B., Kidd, M. S., Lewczuk, A., Kolasińska, A. D., Nieć, D., Michałowska, I. M., Prejbisz, A., Januszewicz, A., Chiarelli, J., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0727 · Cited by 23
SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis
Su, T., Yang, Y., Jiang, L., Xie, J., Zhong, X., Wu, L., Jiang, Y., Zhang, C., Zhou, W., Ye, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1121397 · Cited by 22
Recent progress in the pathologic classification of pheochromocytomas and paragangliomas
Mete, Ö., & Juhlin, C. C. (2024) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2024.101958 · Cited by 22
Chromaffin cell biology: inferences from The Cancer Genome Atlas
Fishbein, L. M., & Wilkerson, M. D. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2795-0 · Cited by 22
A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma
Wakabayashi, H., Inaki, A., Yoshimura, K., Murayama, T., Imai, Y., Higuchi, T., Jinguji, M., Shiga, T., & Kinuya, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-43880-6 · Cited by 22
Ki67 in endocrine neoplasms: to count or not to count, this is the question! A systematic review from the English language literature
Guadagno, E., d’Avella, E., Cappabianca, P., Colao, A. A. L., & De, M. D. B. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01275-9 · Cited by 22
Vascular Pattern Analysis for the Prediction of Clinical Behaviour in Pheochromocytomas and Paragangliomas
Oudijk, L., van Nederveen, F. H., Badoual, C., Tissier, F., Tischler, A. S., Smid, M., Gaal, J., Lussey‐Lepoutre, C., Gimenez‐Roqueplo, A., Dinjens, W. N. M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121361 · Cited by 29
The Molecular Classification of Pheochromocytomas and Paragangliomas: Discovering the Genomic and Immune Landscape of Metastatic Disease
de Bresser, C. J. M., & de Krijger, R. R. (2024) · Endocrine Pathology · doi:10.1007/s12022-024-09830-3 · Cited by 22
Disease monitoring of patients with pheochromocytoma or paraganglioma by biomarkers and imaging studies
Schreiner, F., & Beuschlein, F. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101347 · Cited by 21
Emerging molecular markers of metastatic pheochromocytomas and paragangliomas
Goncalves, J., Lussey‐Lepoutre, C., Favier, J., Gimenez‐Roqueplo, A., & Castro‐Vega, L. J. (2019) · Annales d Endocrinologie · doi:10.1016/j.ando.2019.04.003 · Cited by 21
CT-Based Radiomics Analysis of Different Machine Learning Models for Discriminating the Risk Stratification of Pheochromocytoma and Paraganglioma: A Multicenter Study
Zhou, Y., Zhan, Y., Zhao, J., Zhong, L., Tan, Y., Zeng, W. M., Zeng, Q., Gong, M., Li, A., Gong, L., et al. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.01.008 · Cited by 20
Potential Biomarkers of Metastasizing Paragangliomas and Pheochromocytomas
Snezhkina, A. V., Pavlov, V., Dmitriev, A. A., Melnikova, N. V., & Kudryavtseva, A. V. (2021) · Life · doi:10.3390/life11111179 · Cited by 20
Benign Neurogenic Tumors
Farma, J. M., Porpiglia, A. S., & Vo, E. T. (2022) · Surgical Clinics of North America · doi:10.1016/j.suc.2022.04.007 · Cited by 20
Pheochromocytomas and Paragangliomas
Guo, Z., & Lloyd, R. V. (2015) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000086 · Cited by 19
Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel–Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127)
Gupta, S., Zhang, J., Milosevic, D., Mills, J. R., Grebe, S. K. G., Smith, S. C., & Erickson, L. A. (2017) · Endocrine Pathology · doi:10.1007/s12022-017-9489-0 · Cited by 20

Authors: Kimura, N., Takayanagi, R., Takizawa, N., Itagaki, E., Katabami, T., Kakoi, N., Rakugi, H., Ikeda, Y., Tanabe, A., Nigawara, T., Ito, S., Kimura, I., Naruse, M., & _, _.
Affiliations: National Hospital Organization (JP)
Kyushu University (JP)
Kansai Medical University (JP)
Kyorin University (JP)
St. Marianna University School of Medicine (JP)
Miyagi Prefectural Hospital Organization (JP)
The University of Osaka (JP)
Nihon University Itabashi Hospital (JP)
Tokyo Women's Medical University (JP)
Hirosaki University (JP)
Tohoku University (JP)
Ministry of Health Labour and Welfare (JP)
Kyoto Medical Center (JP)
ORCID: Kimura, Noriko
Takizawa, Nae
Rakugi, Hiromi
Ikeda, Yukihiro
Tanabe, Akiyo
Nigawara, Takeshi
Ito, Sadayoshi
Naruse, Mitsuhide
Venue: Endocrine Related Cancer
Publisher: Bioscientifica
Published: 2014-02-12
Volume: 21
Issue: 3
Pages: 405-414
ISSN: 1351-0088 (ISSN-L)
1479-6821
DOI: 10.1530/erc-13-0494
OpenAlex: W2153367841
Cited by: 393
References: 25
Citations by year: 2026: 29 · 2025: 45 · 2024: 42 · 2023: 41 · 2022: 51 · 2021: 39 · 2020: 24 · 2019: 27 · 2018: 27 · 2017: 27 · 2016: 21 · 2015: 10 · 2014: 6
FWCI: 21.14
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Endocrine Related Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: Shimane University
Tokyo Medical and Dental University
Jikei University School of Medicine
Topics: Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords: pheochromocytoma, paraganglioma, metastasis prediction, tumor grade, SDHB immunohistochemistry, Ki-67 labelling index, comedo necrosis, capsular invasion, survival
MeSH terms: Adrenal Gland Neoplasms, Adult, Aged, Aged, 80 and over, Catecholamines, Female, Follow-Up Studies, Humans, Immunoenzyme Techniques, Male, Middle Aged, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Prognosis, Succinate Dehydrogenase, Biomarkers, Tumor, Survival Rate, Case-Control Studies, Young Adult, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks